The ASCO abstracts are out and can be searched under the iPlanner here:
https://iplanner.asco.org/am2016/#/
So like every year- please post for you relevant abstracts in reply here under the same thread and we do our best to cover them from Chicago!
This time, there will be more of us, so we will be able to report in more detail- now up to you!
9519 - Toxicity associated with ipilimumab and nivolumab (Ipi+Nivo) combination therapy in melanoma patients (pts) treated at a single-institution under an expanded-access program (EAP).
ReplyDelete9525 - Safety data from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).
9554 - Efficacy of nivolumab and ipilimumab (Nivo + Ipi) combination in melanoma patients (pts) treated at a single institution on an expanded-access program (EAP).
9551- Anti-PD-1 tolerance after severe toxicity with ipilimumab therapy in metastatic melanoma patients.
9585 - Neoadjuvant combination immunotherapy with ipilimumab (3 mg/kg or 10mg/kg) and high dose IFN-a2b in locally/regionally advanced melanoma
9586 - Adjuvant nivolumab (NIVO) plus ipilimumab (IPI) for resected high-risk stages IIIC/IV melanoma (MEL).
9588 - Activity of anti-PD1 drugs in uveal melanoma patients
All very interesting and very directly relevant.